POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.

Slides:



Advertisements
Similar presentations
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Advertisements

The Home INR Study (THINRS): Home INR Monitoring as Effective as Clinic-Based Care AK Jacobson, MD American Heart Association 2008 Scientific Sessions:
Independent Project HCAI 5221 Evaluation of Point of Care Bedside Glucose Monitors for Use in a Specialty & Transplant Hospital Mary A. Weidner, BS, MT(ASCP)
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
People. Processes. Performance. Strategies for Clinical Studies & Human Factors Research Ginger Clasby, MS EVP, Business Development Promedica International.
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU- PACT) Warfarin.
Drug Utilization Review (DUR)
Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
CADTH Therapeutic Reviews
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Drug and Therapeutics Committee
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.
The Effects of De-listing Publicly Funded Health Care Services Mark Stabile Department of Economics and Center for Economics and Public Affairs University.
“Put the Power of Predictive Analytics in the Hands of Clinical Researchers” Filippos Katsampouris Marketing Manager Healthcare & Pharmaceutical Accounts.
Dr : Osama Badry Cardiology /Anticogaulation Coordinator Incharge of Anticoagulation Service AWH-HMC/Qatar.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Connected Health: Using patient-centric technologies to change behavior and improve outcomes Joseph C. Kvedar, MD Director Center for Connected Health.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Pharmacoeconomics Research Unit RESEARCH. DECISION SUPPORT. KNOWLEDGE TRANSLATION. CAPACITY BUILDING. Assessment of the pan-Canadian Oncology Drug Review.
1 Comparative Effectiveness Research: Key Issues and Controversies Consumer-Purchaser Disclosure Project Discussion Forum May 5, 2009 Steven D. Pearson,
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
DVT Prevention and Anticoagulant Management
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Point of Care for INR Yvonne Koolman, Nicole Keech, Amy Nelson-Long & Sue Vansteel.
Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
2nd Concertation Meeting Brussels, September 8, 2011 Reinhard Prior, Scientific Coordinator, HIM Evidence in telemedicine: a literature review.
UMASS Memorial Anticoagulation Center Staffing, Budgets, Reimbursement Pamela Burgwinkle APRN-BC,CACP Presented November 4, 2008.
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
Community Pharmacy Presentation for Hospital Pharmacists July 2015.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Terry McInnis, MD MPH President- Blue Thorn, Inc - Mobile Co-Chair- Center for.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Integrating Qualitative Research Into Health Technology Assessment in Canada The CADTH Experience Laura Weeks, PhD Scientific Advisor Kristen.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Presentation Developed for the Academy of Managed Care Pharmacy
A Cost-Effectiveness Analysis of Maternal Genotyping to Guide Treatment in Postnatal Patients.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Spotlight Case Watch the Warfarin!. 2 Source and Credits This presentation is based on the July 2011 AHRQ WebM&M Spotlight Case –See the full article.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
RTI International is a trade name of Research Triangle Institute The Costs of SBI: Findings from the literature Presented by Jeremy Bray, Gary.
‘PhysioDirect’ for patients with MSK problems ECONOMIC MODEL OVERVIEW.
Medication therapy management
Comparative Effectiveness Research: Key Issues and Controversies
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Cornerstone Research Group Inc.
Cost Effective Studies
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Performance Measurement and Rural Primary Care: A scoping review
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
Aug, 2016.
UNT Health Clinical Pharmacist Services
For Patients: Frequently Asked Questions
For Patients: Frequently Asked Questions
Thank you to the Congressional Public Health Caucus, which has brought us today to talk about an important issue that affects patient care and treatment,
Point-of-Care vs Laboratory INR Testing to Optimize Anticoagulation Management.
ASPIRE Workshop 5: Application of Biostatistics
Presentation transcript:

POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH

CADTH’s POC INR Optimal Use Project Objective: To support well-informed decisions about the acquisition and/or optimal implementation of POC INR technology To inform decision makers regarding the accuracy, as well as the clinical and cost-effectiveness of POC INR compared with standard laboratory testing, and compared with other POC INR devices.

Background Approximately 350,000 Canadians are taking oral anticoagulation therapy (OAT) – mostly warfarin Patients must be monitored for over-anticoagulation (possibly resulting in bleeding or hemorrhage) and under- anticoagulation (which could result in blood clots), by measuring International Normalized Ratio (INR) INR monitoring typically occurs every 3-5 weeks in patients stabilized on anticoagulant therapy, however more frequent monitoring is required when starting therapy.

INR Testing The gold standard for monitoring INR is lab testing of blood obtained by venipuncture, in hospital or at an anticoagulation clinic. Point of care (POC) testing is another way to monitor INR. POC testing is testing at or near where a patient is located.

POC INR Testing The aims of POC testing are: Convenience for the patient Faster test results to the health care provider Faster clinical decision-making Improved clinical outcomes and reduced health care resource use

POC INR Testing The POC INR device is called a coagulometer. There are 9 POC coagulometers currently or soon to be available in Canada POC testing for INR involves putting a sample of whole blood, usually capillary blood from a finger stick, onto a test strip. POC devices and test strips are not currently an insured benefit in most Canadian jurisdictions, although they may be available as part of hospital or clinic supply budgets.

Options for Implementing POC INR Patient self-management (PSM) Patient self-tests the INR using a POC device, and self- adjusts the dose of the anticoagulant medication based on the results using a predetermined algorithm or protocol Patient self-testing (PST) Patient self-tests the INR using a POC device and a clinician adjusts the dose of anticoagulant medication based on the results Clinic-based POC INR testing POC testing is performed in a clinical setting such as a physician’s office or anticoagulation clinic.

Questions about POC INR vs. Lab 1.Is POC INR testing as effective as laboratory testing for determining whether INR is within the therapeutic range? 2.In what healthcare settings are there clinical and cost advantages or disadvantages for the use of POC INR testing over laboratory testing? 3.In what healthcare settings are there advantages other than clinical and cost (for example, access to testing or convenience) for POC INR testing over laboratory testing? 4.Is there one particular POC device that is superior to others in terms of clinical, cost, and other advantages?

POC INR vs. Lab Testing What Does the Evidence Say?

POC INR – Clinical Review The clinical review included 48 articles reporting on 47 unique studies, including five RCTs assessing the impact of POC INR testing on clinical outcomes. Only studies evaluating POC coagulometers approved and available for purchase in Canada were eligible for inclusion

Summary of Evidence - Clinical Precision and Accuracy: For INR values within the typical target therapeutic range (2 to 3.5), POC meters produced results comparable to lab Mean difference in INR values between POC INR and lab was within 0.5 units the majority of the time, with a maximum average difference of 0.8. Strong correlation between POC INR and lab However, the difference between INR values between the two methods may increase at high INR values ≥ 3.5 units.

Summary of Evidence - Clinical Time within Therapeutic Range (TTR): POC coagulometers led to an average increase of 6.14% in TTR compared with lab testing, equivalent to approximately 25 days over the course of one year. Clinical Outcomes (Adverse Events): POC meters included in this review did not lead to a statistically significant change in the rate of major bleeding or thromboembolic events or strokes compared with lab.

Summary of Evidence - Clinical Patient Satisfaction and Quality of Life: Limited data on patient satisfaction reported preference for POC over lab testing. Comparison of POC INR devices: Evidence was identified comparing Coaguchek XS, Coaguchek XS Plus, INRatio, i-STAT, or ProTime to laboratory testing.

POC INR - Economic Analysis A cost-effectiveness analysis comparing laboratory testing, patient self-management, patient-self testing, and POC INR testing in a clinic setting in terms of incremental cost per quality-adjusted life-years (QALY) gained. An expanded payer perspective that included patient level costs associated with lab or clinic visits was also conducted to reflect scenarios in which patient travel costs are reimbursed by public payers.

Summary of Evidence - Economic Using retail prices for POC devices ($499 per patient-grade POC and $2,056 for professional-grade POC), and $8.33 per test strip, lab testing was the least costly option with a total cost of $7,033 per patient. Patient self-management (PSM) emerged as a cost- effective option ($13,028 per QALY gained compared to lab) Patient self-testing (PST) and clinic-based POC were more costly and less effective.

Summary of Evidence - Economic When considering patient travel costs for clinic and lab visits, PSM was the least costly option. These results remained robust to variations in estimates of device costs, frequency of testing, health care provider costs in various settings, and patient travel time (such as rural versus urban settings).

POC INR – Bottom Line POC INR testing with any currently available POC INR device is an accurate alternative to lab INR testing. Patient self-management (POC INR testing + dose adjustment) is the most cost-effective option, when feasible. Patient self-testing with health care provider dose adjustment may be an option when lab INR testing is difficult. Clinic-based POC INR testing requires careful consideration of context and costs.

POC INR Newsletter hospitalnews.com/point-care-inr-testing/ 17

POC INR Comparison Tool Lab INR vs. PSM vs. PST vs. Clinic-based Testing Results Patients Sample for Testing Location Average Test Frequency Healthcare professional required Patient or caregiver training required Accuracy 18

POC INR Comparison Tool (con’t) Timeliness TTR Satisfaction/Quality of Life Health Outcomes Estimated Cost/Patient/Year ICER or Cost/QALY Gained Cost-effectiveness Question/Considerations for Implementation bit.ly/1FIoEcL 19

POC INR Costing Tool A tool for decision-makers who are considering the implementation of POC INR technology. The tool helps estimate the total costs of PSM, PST, or clinic-based POC INR testing. Allows users to enter setting-specific information regarding case load, practice patterns, and costs. bit.ly/1FIoEcL 20

21